摘要
本文采用汉防己甲素和羟基磷酸哌喹联合用药的方法对２２５例矽肺进行了临床疗效的观察研究。采取随机配对分组的方法，治疗组和对照组的比例为２∶１。治疗组口服汉甲１００ｍｇ×２／日×６天，羟基哌喹０．５ｇ×１／周，３个月一疗程，连续治疗２年共６个疗程。结果表明治疗组临床症状（咳嗽、咳痰、胸痛、呼吸困难）有明显改善，有效率为７３．７％，明显优于对照组，呼吸系统感染频率明显下降（６２．７％），与对照组比较差异有显著意义，Ｘ线胸片治疗组好转率为１１．８％，稳定率８１．６％，进展率６．６％，与对照组比较差异亦有显著意义。Ⅲ期矽肺及进展快型病例好转率分别为３４．３％、２３．２％。肺功能（ＦＥＶ１．０）治疗后有一定改善。联合用药毒副反应较小，临床疗效肯定，是一种值得推广的治疗矽肺的新疗法。
An observational study on clinical effectiveness of tetrandrine(TD)combined with quinolyl piperazine hydroxy1 phosphate(QPHP)on 225 cases of silicosis was conducted.Subjects were allocated randomly to treatment and control groups,with a ratio of two to one.TD was orally administered in a course of three months with 100 mg twice a day and six days a week and QPHP 0 5 g once a week,for two consecutive years(six courses in total)in the treatment group.Results showed that clinical symptoms,such as cough,expectoration,chest pain,short of breath,were obviously relieved,with an efficacy of 73 7%,significantly superior to that in controls.Frequencyod respiratory infection lowered in the treatment group(62 7%),with a significant difference as compared to the control group.Proportions of improved,stable,and progressive radiographs were 11 8%,81 6%,and 6 6%,respectively,also with a significant difference as compared to the control group.Proportions of improvement in patients with silicosis at stage Ⅲ and rapid progression type were 34 35% and 23 2%,respectively.Lung function improved to certain extent after treatment.Very few adverse reactions were seen in the treatment group,So,it suggests that combination of TD and QPHP is a new method for the treatment of silicosis,with a definite effectiveness,whichmerits to be popularized.
出处
《中国工业医学杂志》
CAS
1997年第1期1-6,共6页
Chinese Journal of Industrial Medicine
关键词
矽肺
汉防己甲素
羟基磷酸哌喹
药物疗法
Treatment of silicosis Tetrandrine Quinolyl piperazine hydroxyl phosphate(QPHP)
